Introduction: The World Health Organization (WHO) publishes a biennial Essential Medicines List (EML) to assist governments in low-resource settings to prioritize their spending on medicines. Currently, no medicines on the EML have a multiple sclerosis (MS) indication. Multiple Sclerosis International Federation (MSIF) prepared an application for inclusion of MS disease-modifying therapies (DMTs) for the 2019 EML together with the regional Committees for Treatment and Research in Multiple Sclerosis (TRIMS) and the World Federation of Neurology. Rationale: The MSIF taskforce categorized 15 DMTs according to their efficacy and risk profiles to ensure the ability to treat as many different clinical scenarios as possible. Three DMTs were selected: glatiramer acetate, fingolimod, and ocrelizumab. Outcome: The WHO Expert Committee did not recommend the addition of any of the DMTs to the EML. They acknowledged the public health burden of MS, the need for effective and affordable MS medications, and the high volume of letters received in support of the application but requested a revised application. Discussion: Despite the negative outcome, the repeated recognition of MS as a global public health burden is sending a powerful message to governments globally that a range of affordable and good quality medications need to be available to health systems and people affected by MS.
Introduction
Healthcare systems are often not able to provide the full suite of treatments available for a particular disease. To assist governments in low-resource settings to prioritize their spending on medicines, the World Health Organization (WHO) publishes an Essential Medicine List (EML). It is not a ceiling, but a floor for what should be available, and currently at least 137 countries are using the concept of an EML. 1 The WHO EML provides guidance when producing national EMLs, tailored to consider the unique health landscape, for example, national disease burden, health system capacities, and sociocultural characteristics of the population. The 2017 WHO EML contains 433 medicines, but none are indicated for multiple sclerosis (MS). To address this disease treatment gap, an application for inclusion of MS diseasemodifying therapies (DMTs) to the EML was prepared by the Multiple Sclerosis International Federation (MSIF). 2 Optimal MS management requires coordinated and comprehensive care from healthcare professionals with expertise in the complexities of MS, 3 yet access to this level of care is limited in many countries due to the high burden it places on individuals and healthcare systems. Untreated relapses and progression of disease restrict participation in usual activities and increase the risk for serious morbidity.
MSIF is an alliance of national MS organizations, and the organizations that we liaise with describe situations ranging from no licensed MS DMTs in a country, to DMT access only for those who pay out-of-pocket. Despite the known efficacy, cost is often beyond governments' ability or willingness to pay. Affordability on a personal level often leaves people without treatment or with cheaper off-label alternatives with less evidence to support their use in MS. In some countries, access is limited to only one type of DMT, often an interferon, licensed for MS over two decades ago. While interferons and other earlier treatments are effective for some, the heterogeneous nature of MS requires additional treatment options for optimal disease management. There is a pressing need for change to ensure clinicians and people with MS have access to high-quality, effective, and safe treatments. Succinctly stated in the recent Lancet Neurology editorial, the current state of treatment and care for patients with MS in low-income countries is "unavailable, unreliable, or unaffordable." 4 In 2015, an application was submitted to the WHO EML to add off-label azathioprine for MS. 5, 6 The application was unsuccessful; however, the WHO Expert Committee acknowledged the public health challenge of MS and requested an independent analysis of the range of treatments available for MS. Due to extensive DMT data reviewed by both the European Academy of Neurology (EAN)/European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 7 and American Academy of Neurology (AAN) 8 Substance Abuse, and the WHO Team-Gender, Equity, and Human Rights were engaged in the process. In December 2018, MSIF adopted the recommendation from the taskforce and submitted the application to the WHO, requesting the addition of glatiramer acetate, fingolimod, and ocrelizumab to the WHO EML.
MS is a global disease, with a rising prevalence that is creating a growing problem for many middle-and low-income countries. The application underscored the importance for the WHO and healthcare systems across the world to engage with the problems associated with treating MS in these countries as seen through the high volume of public letters received from various organizations such as the AAN, Clinton Health Access Initiative (CHAI), the International Pediatric Study Group of MS, national MS organizations, and neurologists from countries such as Zambia, Malaysia, Republic of Guinea, Kingdom of Bhutan, and Tanzania.
Rationale
Due to the variable degrees of disease activity in the relapsing phase and by varying rates of worsening during the progressive phases, 8 factors including individual disease characteristics, differing mechanisms of action, treatment risks, differential treatment response, contraindications to specific agents, side effects, and adherence make access to more than one DMT essential.
The taskforce categorized the DMTs with regulatory approval to help determine which medications to put forward. The (a) biological mechanism of the treatments, for example, mode of action; (b) clinical decision-making considerations, for example, first-, second-, or third-line treatment, treatments used for different age groups or disease courses; and (c) access related considerations, for example, stability of the medication preparation, storage, cost, and availability were discussed. It was concluded that the drivers having several DMTs available were clinical need, ability to treat different disease courses and ability to switch to different therapies. Many countries have a system of first-, second-, or third-line treatment for MS, but there is considerable variation of how these are structured. Considering the MS disease and age spectrum, and the evidence supporting early effective treatment as opposed to escalation therapy, it was concluded that the categories should be related to the disease characteristics and efficacy and risk profiles of the DMTs to ensure the ability to treat as many different clinical scenarios as possible.
Category decisions were based upon phase III clinical trial data of treatments that ultimately led to their regulatory approvals. Due to limited availability of data for off-label agents, as well as the rejected application for azathioprine in 2015, the taskforce did not include off-label agents used for the treatment of MS in its recommendations for the EML.
Based on advice that only a small number of therapies could be proposed to the EML, and after much consideration, the taskforce proposed one therapy from each of the following categories of DMTs that should be available in all health systems:
• • Moderate-efficacy/high-safety therapy (interferon beta preparations, glatiramer acetate); • • Moderate-to high-efficacy oral therapy (dimethyl fumarate, teriflunomide, cladribine, and fingolimod); • • High-efficacy monoclonal therapy (natalizumab, alemtuzumab, and ocrelizumab).
Within each category, further consideration was based on safety, tolerability/livability (including maintaining treatment adherence), monitoring needs, route of administration, licensed use in pediatric-onset and primary progressive MS, and safety profile in pregnancy. Availability of properly evaluated generic, biosimilar follow-on products and/or any related off-label alternatives (with similar mode of action) were also considered.
The three medications selected for application included glatiramer acetate, fingolimod, and ocrelizumab. The proposed medications were chosen based on extensive clinical and post-marketing data, which support their use across the varied disease courses of individuals diagnosed with MS. Women's and children's health is a priority for WHO and as MS disproportionately affects women, safety of DMT use during both pregnancy and pediatric indication remained central to the decision to select these three agents. Availability of high-quality evidence preceded drug costs and the patent life of the DMTs reviewed. Trial data supported the recommendations from each category though it was noted within the application that cross-trial comparisons of MS agents are challenging as primary and secondary endpoints between trials have a high level of variability. It was also recognized that these treatments were not the only ones of value, and that other MS treatments are also efficacious and appropriate for the treatment of MS.
At the time of the EML submission, there were 15 DMTs with regulatory approval for treatment of MS within the global market. An independent analysis of all DMTs approved for MS including a summary of phase III clinical trial data from pivotal trials of the 15 DMTs was completed and submitted as part of the application (Supplemental Material). The summary included primary endpoints representing measurable clinical disease activity and secondary endpoints including clinical metrics.
Within the moderate-efficacy/high-safety category, glatiramer acetate was recommended based on its favorable phase III trial data, paired with over two decades of established safety evidence, including no emergence of serious side effects, no reported risks associated with conception or fetal development, and minimal post-dose monitoring. Based on its favorable safety profile, including pregnancy registry data, glatiramer acetate is considered a safe treatment option in pregnant women 9 as well as pediatric MS. 10, 11 Evidence suggests that delaying the initiation of a DMT or stopping a DMT prior to conception, or immediately following conception, increases the risk of relapse during pregnancy. This can have a substantial negative impact on long-term disability in women living with MS. 12 The ability to treat women of childbearing age with glatiramer acetate is significant for planned or unplanned pregnancies as there is no need to disrupt treatment during pregnancy or postpartum.
Head-to-head comparison trials of glatiramer acetate and interferons have shown similar efficacy in relapse reduction; however, unlike glatiramer acetate, interferons carry the risk of neutralizing anti-drug antibodies. Although interferon preparations were considered for the moderate-efficacy/high-safety category, the requirement for liver function monitoring, common experience of flu-like side effects, the potential impact of anti-drug antibodies, and potential problems with the quality of some biosimilar preparations, 13 interferons were not selected for the application.
Fingolimod, a sphingosine-1-phosphate receptor 1 (S1P1) modulator, was recommended from the moderate-to high-efficacy oral therapy category based on phase III data demonstrating superiority over placebo and interferon beta 1a (Supplemental Material). In addition, fingolimod is the only DMT that holds regulatory approval for the treatment of relapsing forms of MS in individuals 10 years and older, based on clinical trial data in that population. 14 Other oral therapies were considered, though neither dimethyl fumarate nor teriflunomide are approved across the age span, and teriflunomide contains a black box warning in more than one country due to its potential as a teratogen; it also has a long elimination half-life and frequent blood monitoring requirements. Cladribine, though considered by the taskforce, held regulatory authorization for 1 year and lacked postmarket safety data and as such was not included in the application. Siponimod, a second S1P1 modulator, received US Food and Drug Administration (FDA) approval for the treatment of relapsing forms of MS following the application submission so it also was not considered.
Ocrelizumab was recommended from the high-efficacy monoclonal therapy category, based on phase III clinical trials that demonstrated its superiority over placebo and interferon beta 1a (Supplemental Material). In addition to the robust phase III data in relapsing MS, ocrelizumab is the only DMT with favorable phase III data in primary progressive MS, which led to its regulatory approval for both relapsing forms and primary progressive MS. At the time of the EML application submission, long-term follow-up data showed persistent efficacy 15 without new safety concerns. 16 Rituximab, with the same mechanism of action as ocrelizumab, was also considered, though it does not hold regulatory approval for MS. The application stated, while not formally requesting to expand the current EML indication of rituximab to include treatment of multiple sclerosis, it should be noted that rituximab is currently widely used off-label as monotherapy for treatment of multiple sclerosis. In countries without access to ocrelizumab, rituximab may provide a high efficacy treatment option for patients with multiple sclerosis. 2 Natalizumab was carefully evaluated but not selected based on significant safety concerns and monitoring requirements, including ongoing clinical, laboratory, and neuroimaging data to monitor progressive multifocal leukoencephalopathy (PML), hepatic dysfunction, and malignancies, 17 which require additional resources and significant financial costs to healthcare systems and patients. 17 Furthermore, both the AAN DMT guidelines 8 and a 2011 Cochrane review 18 note the safety concerns and recommend caution when considering the use of natalizumab. It is unknown whether low-to middle-income countries have access to the necessary medical technology and expertise in diagnosing or treating patients with PML or whether well-established pharmacovigilance programs are in place. Similarly, alemtuzumab was not selected due to safety concerns, its high monitoring requirements throughout (and beyond) the treatment course, and treatment burden associated with secondary autoimmune complications. 19 
Outcome
In July 2019, the 21st WHO EML was released. While the WHO Expert Committee acknowledged the public health burden of MS and the need for effective and affordable MS medications, they did not recommend the addition of glatiramer acetate, fingolimod, and ocrelizumab to the EML. 20 The Committee felt that the superiority of the medications put forward compared with the benefits, risks, and cost-effectiveness of other available MS therapies was not clear. They also felt that not enough consideration was given to other widely used DMTs, including natalizumab as well as rituximab and azathioprine, which are often used off-label to treat MS in low-resource settings. Finally, they commented being aware of ongoing development of MS treatment guidelines internationally, and that they would welcome a revised application containing a comprehensive review of all relevant available medications for MS, including off-label therapies that may have clinical relevance in the treatment of MS.
Discussion
MS affects >2.5 million people worldwide and is associated with significant morbidity and cost to healthcare systems. DMTs have been demonstrated to alter the course of MS and to have them listed on the WHO EML would be an important tool for advocacy efforts to improve access to treatment in many countries. It would also provide guidance for health systems to ensure they make available a portfolio of therapies that would allow a large majority of patients living with MS to be adequately treated. After careful consideration and review of the evidence by the taskforce, MSIF put glatiramer acetate, fingolimod, and ocrelizumab forward for WHO consideration.
The WHO Expert Committee did not recommend the addition of these agents on the 2019 EML. Despite the negative outcome, the repeated recognition of MS as a global public health burden, and the need for a range of effective and affordable treatments for people with MS, sends a powerful message to governments globally. As the Lancet Neurology editorial points out, medications listed on the WHO EML increase their access to patients globally. 4 Affordable and good quality medications must be available to health systems and people affected by MS to reduce the global burden of MS.
We need patient organizations, professional neurological and other healthcare organizations, international agencies like the WHO, the private sector, and access experts to continue working in collaboration to ensure sustainable change for people living with MS.
